Nanocurcumin(Tehran University of Medical Sciences)(Nanocurcumin(Tehran University of Medical Sciences)) - 在研适应症：肿瘤，类风湿关节炎，实体瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制-

治疗领域

肿瘤免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症

肿瘤类风湿关节炎实体瘤

非在研适应症-

原研机构

Tehran University of Medical Sciences

在研机构

JYANT Technologies, Inc.

Tehran University of Medical Sciences

非在研机构-

最高研发阶段临床阶段不明

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

24

项与 Nanocurcumin(Tehran University of Medical Sciences) 相关的临床试验

IRCT20160809029275N4 / Suspended临床1期IIT

Investigating the simultaneous effect of intrathecal and intravenous injection of autologous mesenchymal stem cells and nanocurcumin consumption in patients with Amyotrophic Lateral Sclerosis (ALS)

开始日期2024-06-21

申办/合作机构

Mashhad University of Medical Sciences

IRCT20240208060938N1 / Suspended临床3期IIT

Investigating the effect of nano curcumin supplementation on drug craving, psychotic symptoms and serum levels A2A, TLR4 receptors and TNF-alpha, IL-6 factors in psychotic methamphetamine consuming patients.

开始日期2024-04-03

申办/合作机构

Kashan University of Medical Sciences

IRCT20220420054592N2 / Recruiting临床2期IIT

Comparing the effect of mouthwash containing curcumin and oral nanocurcumin on gingivitis in patients with chronic gingivitis who referred to Dental School of Shahid Sadoughi

开始日期2024-02-26

申办/合作机构-

100 项与 Nanocurcumin(Tehran University of Medical Sciences) 相关的临床结果

登录后查看更多信息

100 项与 Nanocurcumin(Tehran University of Medical Sciences) 相关的转化医学

登录后查看更多信息

100 项与 Nanocurcumin(Tehran University of Medical Sciences) 相关的专利（医药）

登录后查看更多信息

293

项与 Nanocurcumin(Tehran University of Medical Sciences) 相关的文献（医药）

2024-12-01·Photodiagnosis and Photodynamic Therapy

Evaluation of riboflavin, nanocurcumin, and hydrogen peroxide under light conditions: Reduction of mature dental biofilms and enamel mineral loss

Article

作者: Al Gburi, Ahmed Qays Khudhur ; Ranjbar Omrani, Ladan ; Chiniforush, Nasim ; Afrasiabi, Shima ; Moradi, Zohreh

BACKGROUNDBiofilms are a potential harbor for many microorganisms. The aim of this study was to test the efficacy of riboflavin (Rib), nano-micelle curcumin (NC), and hydrogen peroxide (HP), alone and in combination with the respective light (light-emitting diode (LED) or 980 nm diode laser) on the reduction of Streptococcus mutans and Lactobacillus acidophilus dual-species biofilms and their effect on the enamel mineral loss.MATERIALS AND METHODSThe biofilms were formed on saliva-coated enamel slabs. Then, the biofilms were treated with antimicrobial photodynamic therapy (PDT) based on LED, Rib, and NC photosensitizers and with HP also based on a 980 nm diode laser (n = 8 per group). A crystal violet assay was performed to determine the reduction of the dual-species biofilms. The enamel slabs were analyzed for calcium and phosphorus content by scanning electron microscopy (SEM) and energy dispersive X-ray spectroscopy (EDX).RESULTSWhile HP-PDT showed a reduction of 37% (p < 0.001), PDT with NC resulted in an even greater reduction of dual-species biofilms (40%, p < 0.001) than HP- and Rib-mediated PDT. In the EDX test, no significant difference was found between the control group and the treatment groups.CONCLUSIONSThe use of natural photosensitizers such as NC in PDT has an effect that may be potentially important in reducing caries-causing bacteria.

2024-12-01·Phytomedicine

Effects of metformin and curcumin in women with polycystic ovary syndrome: A factorial clinical trial

Article

作者: Feghhi, Fatemeh ; Sheervalilou, Roghayeh ; Ghaznavi, Habib ; Sepidarkish, Mahdi ; Razavi, Maryam

BACKGROUNDPolycystic ovary syndrome (PCOS) is a common endocrine disorder in women, associated with dyslipidemia, insulin resistance, and hormonal imbalances. Metformin and curcumin have shown promise in improving these metabolic and hormonal parameters individually, but their combined effects in PCOS remain unclear.METHODSWe conducted a randomized, double-blind, placebo-controlled, 12-week factorial trial involving 200 women with PCOS. Participants were randomly assigned in a 1:1:1:1 ratio to receive metformin (500-mg/8 h) + placebo, nanocurcumin soft gel capsule (80-mg/8 h) + placebo, metformin (500-mg/8 h) + nanocurcumin (80-mg/8 h), or double placebo. Lipid profiles, glucose metabolism markers, hormonal parameters, body weight, and body mass index (BMI) were assessed at baseline and week 12.RESULTSThe combination of metformin and curcumin demonstrated significant improvements in lipid profiles, glucose metabolism, hormonal parameters, body weight, and BMI compared to individual agents or placebo. Greater reductions in low-density lipoproteins (LDL) cholesterol, total cholesterol (TC), and triglyceride (TG) levels were observed with the combination therapy, along with increased high-density lipoproteins (HDL) cholesterol. Additionally, the combination therapy significantly improved markers of glucose metabolism and showed synergistic effects in reducing body weight and BMI. Reductions in testosterone and improvements in Follicle-stimulating hormone (FSH) and Luteinizing hormone (LH) levels were also observed with combination therapy.CONCLUSIONThe combination of metformin and curcumin demonstrates superior efficacy in improving lipid profiles, glucose metabolism, hormonal parameters, body weight, and BMI in women with PCOS compared to individual agents or placebo. This highlights the potential synergistic effects of combining these agents for the management of PCOS.

2024-11-01·Journal of Cellular Physiology

RETRACTION: Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID‐19 patients

RETRACTION: S. Tahmasebi, M. A. El‐Esawi, Z. H. Mahmoud, A. Timoshin, H. Valizadeh, L. Roshangar, M. Varshoch, A. Vaez, S. Aslani, J. G. Navashenaq, L. Aghebati‐Maleki, M. Ahmadi, “Immunomodulatory Effects of Nanocurcumin on Th17 Cell Responses in Mild and Severe COVID‐19 Patients,” Journal of Cellular Physiology 236, no. 7 (2021): 5325‐5338, https://doi.org/10.1002/jcp.30233.The above article, published online on 28 December 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor‐in‐Chief, Alexander Hutchison; and Wiley Periodicals LLC.The decision to retract this article follows concerns raised by third parties over the legitimacy of authorship positions. Some listed authors, lacking prior collaboration history with the submitting author group, were added at later stages of the revision process. Subsequent investigation by the publisher has revealed that the article has been published solely on the basis of a compromised peer review process. The retraction is warranted due to the compromised integrity of the article's peer review and the concerns over authorship positions. The corresponding author M. Ahmadi, the first author S. Tahmasebi, and co‐authors H. Valizadeh, L. Roshangar and L. Aghebati‐Maleki disagree with the decision of retraction. Final confirmation could not be obtained by the remaining co‐authors.

100 项与 Nanocurcumin(Tehran University of Medical Sciences) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
类风湿关节炎	临床前	美国	JYANT Technologies, Inc.	2022-01-30
实体瘤	临床前	美国	JYANT Technologies, Inc.	2022-01-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2022	N/A	甲状腺癌	90	40 mg nano-curcumin	(網憲壓鏇衊網遞構範衊) = 鹹顧窪構鏇鑰壓齋醖膚夢築範蓋襯構鏇齋願鹹 (顧鏇廠憲繭製顧製鹽觸, 0.58) 更多	积极	2022-08-08
				80 mg nano-curcumin	(網憲壓鏇衊網遞構範衊) = 糧壓餘願積齋壓齋選膚夢築範蓋襯構鏇齋願鹹 (顧鏇廠憲繭製顧製鹽觸, 0.85) 更多